Foghorn Therapeutics (FHTX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$90.6 million.
- Foghorn Therapeutics' Enterprise Value fell 5705.12% to -$90.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.6 million, marking a year-over-year decrease of 5705.12%. This contributed to the annual value of -$55.5 million for FY2024, which is 3097.24% up from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Enterprise Value is -$90.6 million, which was down 5705.12% from -$73.8 million recorded in Q2 2025.
- Foghorn Therapeutics' Enterprise Value's 5-year high stood at -$50.6 million during Q1 2023, with a 5-year trough of -$213.6 million in Q1 2022.
- Moreover, its 5-year median value for Enterprise Value was -$70.3 million (2023), whereas its average is -$83.2 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Enterprise Value crashed by 182997.39% in 2021, and later surged by 7629.67% in 2023.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Enterprise Value stood at -$101.1 million in 2021, then surged by 48.37% to -$52.2 million in 2022, then plummeted by 53.86% to -$80.3 million in 2023, then skyrocketed by 30.97% to -$55.5 million in 2024, then tumbled by 63.35% to -$90.6 million in 2025.
- Its last three reported values are -$90.6 million in Q3 2025, -$73.8 million for Q2 2025, and -$61.0 million during Q1 2025.